Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1835 results
October 2020
-
Press Release
Novartis acquires Vedere Bio, adding novel optogenetic gene therapy technology for treating blindness
Acquisition expands the Novartis footprint in ophthalmology and enhances the company’s position as an AAV-based gene therapy powerhouse.Novartis gains two pre-clinical optogenetic AAV gene therapy… -
Press Release
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19
Novartis has been granted an option to in-license global rights of MP0420 and MP0423 - multi-targeted direct acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-… -
Key Release
Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance.
Q3 net sales from continuing operations1 were in line with prior year (cc2, +1% USD): Growth drivers included Entresto USD 632 million (+45% cc), Zolgensma USD 291 million (+79% cc), Cosentyx USD… -
Key Release
Novartis im 3. Qu. mit solider Performance: operatives Kernergebnis steigt um 11%, Nettoumsatz auf Vorjahresniveau, starke Pipeline-Fortschritte; Jahresprognose für operatives Kernergebnis angehoben
Im dritten Quartal 2020 lag der Nettoumsatz der fortzuführenden Geschäftsbereiche1 auf dem Niveau des Vorjahres (kWk2, +1% USD): Zu den Wachstumsträgern gehörten Entresto (USD 632 … -
Key Release
Novartis au T3: performance solide, croissance de 11% du résultat opérationnel core, chiffre d’affaires net proche de l’an dernier, pipeline en fort progrès; hausse du résultat opérationnel core prévu
Chiffre d’affaires net des activités poursuivies1 au T3 en ligne avec celui de l’exercice précédent (tcc2, +1% USD): Les moteurs de la croissance ont été notamment Entresto USD 632 millions… -
Press Release
Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)
C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need.1–3 Iptacopan (LNP023) is a potential first-in-class, oral,… -
In The News
Overcoming manufacturing challenges
Novartis Technical Operations adapts to meet drug donation plans and ensure business continuity. -
Press Release
Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)
Orphan drug designation is reserved for medicines treating rare, life-threatening or chronically debilitating diseases IgA nephropathy (IgAN), while rare, is the most common form of… -
Press Release
Novartis receives US Food and Drug Administration (FDA) Orphan Drug Designation for branaplam (LMI070) in Huntington’s disease (HD)
Huntington’s disease is a rare, inherited neurodegenerative disease that leads to progressive disability and deathThere are no approved disease modifying therapies that delay disease onset or slow… -
Key Release
Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol
If approved, inclisiran will be the first and only small interfering RNA (siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia1Cardiovascular disease (CVD) claims 3.9… -
Press Release
Novartis received European Medicines Agency (EMA) PRIME designation for iptacopan (LNP) in C3 glomerulopathy (C3G)
The European Medicines Agency has granted iptacopan a priority medicines (PRIME) designation in C3 glomerulopathy (C3G). PRIME is granted for medicines that may offer major therapeutic advance… -
Featured News
World Sight Day 2020
Learn how we’re working with partners like the International Agency for the Prevention of Blindness to eliminate preventable blindness.